Press kit,on the record.

NewGenPharma AG is a Swiss pharmaceutical research group developing central-nervous-system stimulants and manufacturing GMP-aligned API intermediates from its facilities in Zug and Basel-Landschaft.

NewGenPharma AG is a Swiss pharmaceutical research group founded in Zug in 2023. It develops central-nervous-system stimulants — phenethylamines, tropane analogs, eugeroics and 2-aminoindanes — and manufactures GMP-aligned API intermediates for academic and industry partners across Europe. Every batch carries a full Certificate of Analysis, ICH-Q3A/D residual profiles and DMF-ready documentation.

NewGenPharma AG is a Swiss pharmaceutical research group headquartered in Zug and with laboratories in Basel-Landschaft. Founded in 2023 by a team of senior medicinal chemists, process engineers and clinical scientists whose combined résumé spans three decades at tier-one Swiss and German houses, the group focuses on the discovery of central-nervous-system stimulants and on the manufacture of GMP-aligned API intermediates. Every batch leaves the facility with a full Certificate of Analysis, ICH-Q3A/D residual profiles and DMF-ready documentation. NewGenPharma serves academic collaborators, contract research organisations, and API buyers across Europe.